Board-Certified Oncologist & Hematologist in Puyallup and Bonney Lake, WA
Dr. Kanaan completed his Hematology & Oncology Fellowships at Michigan State University and the University of Arizona in Tucson. Dr. Kanaan did his Internal Medicine Residency at McLaren Regional Hospital in Flint, Michigan, and his undergraduate degrees in Medicine and Surgery are from Amman, Jordan.
In his spare time Dr. Kanaan enjoys outdoor activities such as hiking, kayaking and mountain biking. He also enjoys soccer, swimming, diving, running and cycling.
Medical School: University of Jordan in Amman, Jordan
Residency: McLaren Medical Center at Michigan State University
Fellowships: Michigan State University, University of Arizona
Board Certifications: Medical Oncology, Hematology, Internal Medicine
Peer-Reviewed Publications:
- Dumbrava EE, Stinchcombe TE, Gounder M, et al., Kanaan M, et al. Milademetan in advanced solid tumors with MDM2 amplification and wild-type TP53: Preclinical and phase II clinical trial results. Clin Cancer Res. 15 Oct 2025; 31(20): 4255-4264. DOI: 10.1158/1078-0432.CCR-25-0762
- Mallahan S, Gajra A, Blau S, et al., Kanaan M, et al. Optimizing clinical trial subject selection: Insights from Exigent Research Network and the Tempus AI TIME program collaboration. AI Prec Oncol. 18 Dec 2024; 1(6). DOI: 10.1089/aipo.2024.0030
- Dumbrava EE, Chen CT, Cote GM, et al., Kanaan M, et al. Abstract B034: A phase 2 basket study of the oral MDM2 inhibitor milademetan for MDM2-amplified advanced solid tumors (MANTRA-2). Mol Cancer Ther. 1 Dec 2023; 22(12_Supplement): B034. DOI: 10.1158/1535-7163.TARG-23-B034